Low Incidence of Treatment-Induced Peripheral Neuropathy (PN) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Treated with Single-Agent Carfilzomib

VBCC - March 2013, Volume 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts
Thomas Martin
Ravi Vij
Ashraf Z. Badros
Leanne McCulloch
Sundar Jagannath University of California-San Francisco, San Francisco, CA, USA; Washington University School of Medicine, St. Louis, MO, USA; Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA; Onyx Pharmaceuticals, South San Francis

Background: Treatment of patients with RRMM can be challenging because of debilitating PN caused by the disease itself or by MM treatments. Neuropathy at diagnosis is prevalent (20–54%, depending on evaluation type [Richardson PA, et al. J Clin Oncol. 2009]) and can commonly be exacerbated by MM treatments (eg, bortezomib- or thalidomide-induced PN; BIPN or TIPN). PN reduces quality of life and leads to increased PN-related healthcare expenditures (eg, diagnostic testing and pharmaceutical and non-pharmaceutical interventions [Snowdon JA, et al. Br J Haematol. 2011]). One group has estimated that a single event of treatment-related Grade 3/4 PN costs more than $1,000 (Durie B, et al. J Med Econ. 2013; Epub). Carfilzomib is a selective proteasome inhibitor recently approved in the US for RRMM that, in preclinical models, does not induce neurodegeneration as seen with bortezomib and, in clinical studies, is associated with low rates of PN.

Objectives: An analysis of the PN safety profile for single-agent carfilzomib was performed in a cross-trial safety analysis of 526 patients from 4 phase 2 studies.

Methods: AEs were analyzed from the following studies: PX-171-003-A0, PX-171-003-A1, PX-171-004, and PX-171-005 (NCT00511238, NCT00530816, NCT00721734), in which carfilzomib was dosed at 20−27 mg/m2 in 28-day cycles for all studies except 005 (15−27 mg/m2). Patient assessments included neuropathy history and baseline neuropathy status. An aggregate of PN terms including peripheral neuropathy, neuropathy, peripheral sensory neuropathy, and peripheral motor neuropathy were used in the analysis of PN.

Results: The majority of patients in these studies (84.8%) had a history of PN due to previous therapy (42.6% due to bortezomib, 43.3% thalidomide, and 5.9% lenalidomide), with 71.9% of patients having active PN just prior to study entry (all Grade 1 or 2). During treatment with carfilzomib, PN worsened or emerged in only 13.9% overall. Among the 526 patients, 41 (7.8%) experienced Grade 1 PN, 25 (4.8%) Grade 2 PN, and 7 (1.3%) Grade 3 PN. Notably, no ≥Grade 4 PN was reported. In response to a PN-related AE, only 1 patient (0.2%) discontinued treatment and 4 (0.8%) required a dose modification. Of significance, 330/378 (87.3%) of the patients with baseline PN had stable or improved neuropathy during study treatment and did not report any PN-related AEs within 30 days of their last dose of carfilzomib.

Conclusions: In contrast to currently approved MM therapies, carfilzomib is associated with a low rate of treatment-emergent PN, even in patients with a history of PN, and does not exacerbate PN in patients with pre-existing neuropathy. Additionally, there was a low rate of dose reductions or discontinuations due to PN. Future findings from comparative trials will determine whether complications and costs associated with BIPN and TIPN can be minimized with carfilzomib treatment.

Related Items
Perspectives of Quality Care in Cancer Treatment: A Review of the Literature
Lisa M. Hess, PhD, Gerhardt Pohl, PhD
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Is Oral Electrolyte Replacement More Effective than IV Replacement in the Oncology Population?
Rebecca Martin, BSN, RN, OCN, Joanne Growney, RN, MA, ANP-BC
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Cost Considerations for New Oral Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously
Lorie A. Ellis, Zoe Clancy, R. Scott McKenzie, Mekre’ Senbetta
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Cost Analysis of Bortezomib Retreatment Compared with Switching to Carfilzomib in Patients with Relapsed Multiple Myeloma Previously Treated with Bortezomib
Kevin B. Knopf, MD, MPH, Marie-Hélène Lafeuille, MA, Jonathan Gravel, MS, Patrick Lefebvre, MA, Liviu Niculescu, MD, Abbie Ba-Mancini, MBA, Esprit Ma, MPH, Mei Sheng Duh, MPH, ScD
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Imatinib Can Still Be Used as 1st-Line for Treating Chronic Myelogenous Leukemia
Wesley Wong, PhD
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Wait Time and Patient Satisfaction—Improving Outcomes Can Be as Easy as Child’s Play
Julia Whiteker, Ann Bredensteiner
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Say Ahh! Making Sense of Oral Assessments for Mucositis
Joanne Growney, MA, RN, ANP-BC, OCN, Rebecca Martin, BSN, RN, OCN, Phyllis McKiernan, RN, MSN, APN-BC, Joan Collela, RN, DNP, APN-BC, NP-C, Claudia Douglas, RN, MA, CNN, APN-C
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Impact of Granulocyte Colony-Stimulating Factor and Treatment Modification on Eribulin Mesylate Therapy in Metastatic Breast Cancer Patients with Neutropenia
Gluck S, Yardley D, Belk K, Craver C, Cox D, Faria C, University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Tennessee Oncology, PLLC, Nashville, TN; MedAssets, Inc., Charlotte, NC; Eisai Inc., Woodcliff Lake, NJ
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Impact of Treatment Modification on Treatment Duration in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
An Assessment of Racial Differences in Toxicities and Supportive Care in Patients with Metastatic Breast Cancer (MBC)
George Dranitsaris, Nancy Beegle, Traci Kalberer, Zhixiao Wang, Claudio Faria, Sibel Blau
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology